Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M M Lederman

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
The Journal of Infectious Diseases|July 1, 1995
Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacsM M Lederman, J B Jackson, B L Kroner, et al.
The Journal of Clinical Investigation|July 3, 1998
In vivo analysis of Fas/FasL interactions in HIV-infected patientsA D Badley, D H Dockrell, A Algeciras, et al.
HIV Medicine|May 18, 2016
Systemic inflammation and liver damage in HIV/hepatitis C virus coinfectionK V Shmagel, E V Saidakova, N G Shmagel, et al.
The Journal of Infectious Diseases|March 9, 1999
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end pointsH Wu, D R Kuritzkes, D R McClernon, et al.
The New England Journal of Medicine|October 10, 1996
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study TeamS M Hammer, D A Katzenstein, M D Hughes, et al.
Clinical Immunology (Orlando, Fla.)|February 13, 2001
Characterization of high-risk HIV-1 seronegative hemophiliacsJ R Salkowitz, S F Purvis, H Meyerson, et al.
Mucosal Immunology|February 4, 2016
Prevention of SHIV transmission by topical IFN-β treatmentR S Veazey, H A Pilch-Cooper, T J Hope, et al.
AIDS (London, England)|March 14, 2000
Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials GroupH Valdez, K Y Smith, A Landay, et al.
The Journal of Infectious Diseases|July 4, 1998
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315M M Lederman, E Connick, A Landay, et al.
The Journal of Infectious Diseases|December 23, 1999
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic responseE Connick, M M Lederman, B L Kotzin, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
The Journal of Infectious Diseases|July 1, 1995
Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacsM M Lederman, J B Jackson, B L Kroner, et al.
The Journal of Clinical Investigation|July 3, 1998
In vivo analysis of Fas/FasL interactions in HIV-infected patientsA D Badley, D H Dockrell, A Algeciras, et al.
HIV Medicine|May 18, 2016
Systemic inflammation and liver damage in HIV/hepatitis C virus coinfectionK V Shmagel, E V Saidakova, N G Shmagel, et al.
The Journal of Infectious Diseases|March 9, 1999
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end pointsH Wu, D R Kuritzkes, D R McClernon, et al.
The New England Journal of Medicine|October 10, 1996
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study TeamS M Hammer, D A Katzenstein, M D Hughes, et al.
Clinical Immunology (Orlando, Fla.)|February 13, 2001
Characterization of high-risk HIV-1 seronegative hemophiliacsJ R Salkowitz, S F Purvis, H Meyerson, et al.
Mucosal Immunology|February 4, 2016
Prevention of SHIV transmission by topical IFN-β treatmentR S Veazey, H A Pilch-Cooper, T J Hope, et al.
AIDS (London, England)|March 14, 2000
Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials GroupH Valdez, K Y Smith, A Landay, et al.
The Journal of Infectious Diseases|July 4, 1998
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315M M Lederman, E Connick, A Landay, et al.
The Journal of Infectious Diseases|December 23, 1999
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic responseE Connick, M M Lederman, B L Kotzin, et al.
Pageof 14